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ntroducton:
The polyunsaturated fatty acid, arachidonic acid (AA},
can be converted through cyclo-oxygenase and/or lipoxygenase
catalyzed reactions to form prostaglandins, thromboxanes,
leukotrienes (62), and other products (for review see 76).
However, RA must be available to these enzyme systems as a
free fatty a.ci in order for these metabolic reactions to
take place (48,101). Free AA levels are normally held to
very low concentrations within cells (39,47) and yet AA may
comprise a substantial proportion of the coustituent fatty
acid in cellul.r iipi8 pools. Generally, AA is est.erified
with complex lipids including cholestery! esters
tzigiycerides, and phosphoiipds. Release of AA from complex
].ipids is her.,eore a physiological prerequisite for th
production of eicosanoid metabolites. While the importance
of prostanoids in cell and tissue physiology has been
recognized for several decades, it is only recently that
considerable progress has been made in the understanding of
mechanisms regulating AA release from cellular iipids,
primarily phospholipids.
Unique to the process of AA metabolism is the capacity
for cells to selectively release AA from phospholipid stores
following membrane perturbation with a variety of agents
including hormonal, chemical, and mechanical stimuli. In
addition, increased AA metabolism is frequently accompanied
by rapid compositional changes in membrane phospholipids,
alterations in membrane fluidity, increased levels of cell
associated Ca++ levels, and alterations in enzyme activity
(68). The interdependence of these events in regulating AA
metabolism is, as yet, not clearly defined. In addition,
the ubiquity of increased AA metabolism following membrane
perturbation is by no means established throughout the
spectrum of cell types existing in nature
The purpose of this investigation was to examine AA
metabolism in two cell types which have not been previously
characterized in this respect. AA metabolism was first
exam ned in the osteoblast-like clonal ce].,l line,
!7,2’ "8, *o!lowing stimulation with .larahyroid ho’mone
(PT[). RCS !7/2"8 cells have been shown to release
physiolog.ically significant amounts of the AA metaboliC, e,
prostaglandin E 2 (PGE 2), in culture (71) in addition,
these cells demonstrate membrane receptors for PTH and
several biological responses to PTH thought to be
characteristic of osteob!asts, i.e., increased cyclic-AMP
(cAMP) levels and decreased alkaline phosphatase activity
(54) AA metabolism was also examined in human mononuclear
phagocytes (HMP) following stimulation with the complement
fragment, C3b, or lipopolysacchide (LPS). C3b and LPS have
been shown to stimulate immunoreactive prostagiandin E
(PGE) and thromboxane B 2 (TXB2) release from freshly
isolated HMP in culture (72,80). Prostaglandin release from
stimulated monocytes and/or macrophages may be important in
the pathogenesis of chronic inflammatory diseases including
periodontal disease.
Literature Review:
Arachidonic acid serves as the substrate for the
synthesis of prostaglandins (PG) thromboxanes,
prostacyclins leukotrienes (LT), and other products. The
end products of AA. metabolism are not stored in cells or
tissues but are rapidly synthesized and released following
appropriate cell stimulation (42,91). With only a few
notable exceptions, the biological effects of eicosanoid
metabolites are thought to occur locally in the area of
release as the.se compounds are generally very labile. The
importance of PGs and LTs in cell physiology is .evidnced.by
the multitude of cell and tissue effects manifested by th
various o2cosanoid products. PGs have been shown to play
important regulatory roles in inflammatory reactions (99)
digestive function (69), cardiovascular and renal physiolgy
(50), reproduction (27), systemic homeostasis (41), and
platelet aggregation (5 ). Thromboxane and prostacyclin are
also very important in systemic homeostasis and platelet
function (2). The recently discovered leukotrienes have not
been extensively characterized with respect to cell and
tissue effects with one notable exception. Slow reacting
substance of anaphy!_axis (SRo A), identifiable for several
decades only as an activity, has recently been shown to be a
mixture of leukotrienes C 4 and D 4 (3). While AA metabolite
production has been recognized as an important mechanism
for modulating cell and tissue function, there are many cell

Figue . Reaction scheme for for the convezs+/-on of
arachidonic acid to PGG 2 and PGH2. The prominent feature of
this reaction is the formation of the cyclopentane ring with
closure of carbons 8 and 12.
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is ultimately dspendent on the availability of free AA for
enzymatic conversion. It has also beena general assumption
in the prostaglandin field that the rate limiting step in
the production of eicosanoids is the rate of release of AA
from lipid stores within cells (97). The release of
esterified AA from lipid sources is regulated by several
metabolic pathways However, interest has recently focused
on phospholipid metabolic pathways which lead to release of
AA following stimulation of target cells with hormonal or
chemica! agents. Increased phospholipid metabolism is
assoc ated ith preferential r61ease of AA without
comparable ,’lase of other constituent fatty acids (369
Pr ee r e n t i al esse of AA can be attributed in part to the
positio:i ,’pecificity of AA incorporation into,
phospholipids. AA is esterified predominantly on the number
glycerol carbon of phospholipids. Generally, saturated
fatty acids are localized to the number 1 carbon of the
glycerol moiety of phospho!ipids whereas the number 2
position is usually occupied by unsaturated fatty acid
moieties (96), In addition, many cell types demonstrate
enrichment for AA in particular phospholipid classes, most
frequently in pho sphatidyl choline (PC) and
phosphatidylinositol (PI) (I). Although the mechanisms
regulating enrichment for AA in certain phospholipids are
poorly characterized, those phospholipids which are
principal stores for AA are frequently involved in metabolic
processes which lead to selective release of AA. Several
pathways have been described to date:
Sequential methylation of phosphatidylethanolamine (PE)
to form PC followed by release of AA from PC through the
action of a PC-specific phospholipase A2.
2) PI breakdown to diglyceride (DG) with subsequent release
of AA from DG through the action of diglyceride lipase.
3) Breakdown of PI to DG followed by conversion of DG to
phosphatidic acid (PA). AA is then released from PA through
the action of a PA specific phospholipase A 2.
Fhospholi..d m6thylation and AA release
Two .:incipa! pathways eist -’.n cells for thee synthe, sis
of PC: 1) transfer of phosphocholine from CDP-cholin. to 1,2
catalyzed by CTP: phosphocho
transferase (81) and 2) three sequential methy!ati.cms of the
amine residue of PE through the action of methyltransferase
enzymes (12,26). The later pathway has been shown to
accelerate following receptor-ligand interaction in a
variety of cell types (31). The methylation process has also
been associated with flipping of the monomethyl-PE
intermediate across lipid bilayers as there is an asymmetric
distribution of methyltransferase enzymes (31). The sequence
of events is as follows: on the cytoplasmic side of the
plasma membrane, PE undergoes a single methylation through
the action of methyltransferase I and is flipped to the
exterior side of the plasma membrane. The monomethyl-PE then
undergoes to additional methylations through the action of
methyltransferase II to yield PC.
process is associated with alterations
Stimulation of this
in membrane fluidity
(32), receptor expression (88), Ca dependent processes (40),
and biological responses such as histamine release from mast
cells, T lymphocyte blastogenesis, chemotaxis, and cell
differentiation (31). This process is also associated with
increased cellular lysophosphatidylcholine (lysoPC) levels
and. enhanced release, of AA both resulting from increased
phospholi.ase A 2 action on PC (31). In addition,
of ce.lls .:[th .he methyltransferase inhibitor,
treatmeut
blocks me.t.hylation of PE, 2) inhibits biological, effects
such a,, ",i-tamine release, and 3)preve’,,ts the
releas, of p encorporated radiolabelled AA (.i) Lth ’-,
there is a close association between AA release and
increased phospholipid methylation in certain cell. types,
there is no direct evidence which establishes PC as the
single source 0f released AA.
FI.-PA cycle and release of AA.
In 1953, Hokin and Hokin noted, that acetylcholine
stimulated rapid uptake of 32p04 into PI in exocrine
pancreas (33). This finding led to the proposal that
phospholipid metabolism might be intimately related to the
action of this neurotransmitter in pancreatic cells. The
effect observed by the Hokins described a small aspect of
what is now called the PI-PA cycle. According to current
evidence, hormonal or chemical stimulation of certain cells
is associated with rapid degradation of PI thro.ugh the
action of a PI specific phospholipase C (7). This enzymatic
breakdown yields I ,2-diacylglycerol (DG) and
phosphoinositide. DG may then undergo phosphorylation
through the action of diglyceride kinase to produce PA or
may be cleaved to monoglyceride and AA through the action of
diglyceride lipase (6). PA can then be reconverted to PI
through the action of two enzymes, CDP-phosphatidate cytidyl
transferase and CDP I ,2-diacylglycerol-inositol
phosphatidyltrnsferase. The salient features of this
pathway are depicted in Figure /.
Stimulated phospholipid labelling ?githu.n th PI-PA
cycle hs been described for platelets (7) rcu.trophils
(25), macrophages (.4), renal tissues (!5), neural tissues
(22), and others (33,67), following treatment with a variety
of hormones or cAemicals. As was described earlier,
stimulation of phospholipid turnover in the PI-PA cycle can
be associated with increased release of AA either from DG
through DG lipase (6) or from PA through a PA specific
phospholipase A2 (8). In addition to increasing AA release,
the PA-PI cycle may contribute to cell stimulation through
several other mechanisms. DG has been shown to stimulate
protein kinase C activity (42,92). Also, lysophosphatidic
acid has been proposed to act as a ca ionophore in cell
membranes (49) and has been shown to promote Ca permeability
16
Figure /.o Phosphollpid turnover in the phOsphatidylinositol-
phosphatidate cycls. Phosphatidylinositl is rapidly broken
down to diglyceride (DG) and inositide through the action of
PI specific phospholipase C (a). DG is then either
d.eacylated through DG lipase (c) to yield monoglyceride and
arachidonic acid (AA) or is phosphorylated through DG kinase
(B) to produce phosphatidic acid (PA). Phosphatidic acid may
then be deacylated through the actionof phospholipase A 2
(d) to yield AA and lysophosphat+/--d+/-c acid (LPA) or can be
converted to PI through the action of CDP-phosphatidate
cytidyl tansferase (e) and CDP 1,2-diacylglycerol-i.nos.?cl
phosphatidyltr.nsferase.
AA
CDP-DG
d
PI
PA
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in artificlal lipid bilayers (84). In summary, increased
phospholipid turnover in the PA-PI cycle has been associated
with and/or may elicit a variety of molecular signals in
stimulated cells including increased release of AA.
Recently, _rapid breakdown of another group of
phospholipids, the polyphosphoinositols, has been observed
following hormonal or chemical stimulation of several cell
types (4,30,60). Although the breakdown of these
phospholipids has not been directly linked to a stimulation
of AA release, they appear to be of sufficient importance to
the previouslv described phospholipid proceses to b.
mentioned here. Polyphosphoinositols include
phosphatidylinositol ,5--bisphosphate (PIP 2) and
phosphatidylinositol .-diphosphoinositol (PIP ) whifzh
constitute quantitatively minor phospholipids in biological
membranes. Following stimulation of certain cells with
hormones or neurotransmitters, PIP and PIP 2 are rapidly
hydrolyzed by phospholipase C to form inositol bisphosphate
and inositol trisphophate, respectively, as well as DG (4)-
This process is similar although more rapid in onset than
the previously described breakdown of PI in the PI-PA cycle
(4). Inositol triphosphate then stimulates the release of Ca
from internal cellular stores (56) whereas DG stimulates
protein kinase C activity as described previously (42,92).
Ca release from internal stores is thought to precede the
influx of Ca from extracellular medium which in many cases
is associated with the previously described alterations in
phospholipid metabolism and increased release of AA.
However, there is no evidence to date suggesting a cause and
effect relationship between PIP and PIP 2 breakdown and Ca
influx into cells. On the other hand, the
inte rr elat i onshi ps between the PI-PA cycle and
polyphosphoinositol breakdown togethen.with the relationship
between inositol trisphosphate production and Ca release
from Intracellular stores suggest that these processes are
at least indirectly related to stimulation of AA release.
Variatiom in me,chanisms of AA release between cell types.,,
The ,.eviously described phospholipid metabolic
athway e not found in all cell types nor are they the
oriy path,,ays known to exist. The mechanisms of AA release
from phospholipids can vary between tissues, between
types within the same tissue,, and within the same cell type
depending on the species and stimulus. For example, AA
release from human neutrophils treated with synthetic
chemoattractant occurs primarily through phospholipase A 2
cleavage of PI (103). Following stimulation of human
platelets with thrombin, AA is released predominantly
through the action of phospholipase on PC (104). In
peritoneal macrophages stimulated with zymosan, deacylation
of PI appears to be the dominant mechanism for the release
of AA (20). In contrast, Kroner, et al have shown that free
AA levels are primarily regulated by reacylation mechanisms
2O
involving lysophosphatide-acyltransferase catalyzed
reactions (45) Finally, there are many cell types which
manifest no alterations in phospholipid metabolism and/or AA
release when treated with appropriate physiological stimuli
(60). In summary, there are many exceptions to the metabolic
pathways outlined previously for regulating AA release.
Furthermore. there are a great number_ of cell types which
have not been studied with respect to phospholipid
metabolism and AA release
The purpose of this investigation was to study AA
metabolism and release from two previously uncharacterized
cell types. The first chapter describes ex,periments
examining phospholipid-AA metabolism in the osteoblast-like
c!onal cil R 17/2 8, following stimulation w+/-th PTH. Th
second chapter describes the partial characterization of AA
metabolism in human peripheral blood m0nocytes i_n v_i_tr_o_
stimulated with the complement fragment, C3b, and
lipopolysaccharide.
Chapter I.
Arachidonic Acid-Phospholipid Metabolism in ROS 17/2"8 Cells
Grown in Microcarrier Culture
21
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Abstract:
The present study examined the effect of PTH on arachidonic
acid metabolism and release from ROS I 7/2"8 cells
prelabelled for 2 hr with 3HSAA. ROS $7/2"8 cells were
first grown in microcarrier culture to obtain large numbers
of substrate attached cells. It was found that PTH (I0-8M)
slightly stimulated 3H release from K3HSAA prelabelled cells
after 2 hr of hormonal stimulation but not after 3 or 24
hrs. In contrast, A23187 (SUM), a Ca +.+ ionophore, was a
potent stimulator of K3HS release for up to 2 hr. PTH did
no+ alter [H} ].abel content of R0S 17/2"8 PE, PI,, orPC
after 2. hr of exposure Additional experiments examined the
effect of PTH on phospholipid [32pIP04 labelling in order to
assess al.(:rations in phospho!ipid
to have no significant effect on
turnover PTH was sCn
[32pIP04 uptake into
PI, PC, and PA in ROS 17/2"8 cells suggesting that
phospholipid turnover is not stimulated following hormonal
treatment. These results indicate that arachidonic acid and
phospholipid metabolism
sufficiently affected by
arachidonic acid release as a
production.
by ROS 17/2"8 cells is not
PTH to implicate endogenous
mechanism for increased PGE2
Introduction:
PGE2 release from rodent osteosarcoma clonal cells has
been correlated with the expression of osteoblastlc
phenotypic characteristics, i.e., decreased alkaline
phosphatase activity and increased cAMP levels following
parathyroid hormone (PTH) stimulation (70). The
cyclooxygenase catalyzed production of prostanoids,
including PGE2, is controlled by the availability of free
arachidonic acid (AA) which is normally held to very low
"levels within cells (100). Two principal mechanisms have
been identified whereby cells increase free AA iev!s:,"b9
decreasing the rate of AA acylation into lipid stc:res, within
cells (5). and by increasing the rate of AA release from
lipid st.o.,es (9). Recently, phospholipid turnover
observed in association with the release of AA from,,varivus
cell types (29,34,93). Phospholipid turnover events can be
initiated by receptor-ligand interaction (22) and can be
associated with increases in cellular Ca levels (56),
activation of phospholipase C and/or A 2 activity (104), and
increased AA release. There is no substantial evidence
indicating that receptor-ligand interaction leads to
inhibition of AA incorporation into cellular lipids. The
release of elevated amounts of PGE2 by osteoblastic cells in
culture indicates that arachidonic acid (AA) is available
for conversion to PGE 2. It has also been demonstrated that
exogenous AA can be converted to PGE2 by osteob!ast enriched
calvaria cells and osteoblast-like clonal cells (60,70).
Recent studies have also shown PTH stimulation of PGE
release from osteoblast-enriched cells in culture (53).
The purpose of the this study was to determine whether
PTH can stimulate release of arachidonic acid from ROS
17/2"8 osteoblast-llke clonal cells in a manner consistent
with cell regulated release resulting from increased
phospholipid turnover.
Msterials and Methods:
Microcarrier cll culture.
ROS I. 7/28 cells were passaged and ,.,ro,,n’’.. n
micro,:a’rer cultu:’e (MC). This clture technique as Cho::on
because llz"ge numbers of cells are conveniently produccd
e,:vpriment, can be performed without enzymatically reieasin<
cells and the entire cell culture can be uniformly labelled
prior to aliquoting cell samples for experimental use.
Briefly, this technique involves growing cells on collagen
coated dextran beads (Cytodex IIi beads, Pharmacia)
maintained in suspension with stirring at 30-35 rpm in a
microcarrier spinner flask (250 ml, Bellco). M+/-crocarrier
2/g obeads are 100-150 m in diameter and provide 0.2-0.3 m
surface area for substrate attached cell growth. Subculture
of ROS 17/2"8 cells was accomplished by aliquoting 30 ml of
confluent bead suspension into a sterile bottle. After the
beads settled, the medium was decanted and 50 ml of Ca-Mg-
free Hank’s buffer containing 0.01 trypsin (Sigma) was
added to the settled beads. After standing for 5 min at
37C, the medium was decanted and a second 50 ml aliquot of
trypsin containing buffer was added The mixture was alloed
to stand for 15 to 20 minutes after which most cells were
released with gentle awirling. The beads were allowed to
settle, the cell suspension decanted and the ROS cells
pelleted and resuspended in F2 medium. Inoculation of a
new culture was carried out by adding 2.0 x 07 cells to a
spinner flask holding 0.5 g of thrice washed Cytodex III
beads in 50 ml of F-S2 medium containing I kanamycin
s]ifate and 5Z fetal calf serum (FCS). The be,d suspens,ioz
,was then,2tir.red continuous]y for 7 days at .5-40rpm at
37C At two day intervas, cell feeding was accomplished b.
allowing ;he beads to settle followed by medium exchang..e,
Medium was equilibrated with an atmosph.re of 5 CO 2 in air
All spinner flasks were wrapped in foil to prevent exposure
of the proliferating cells to light.
Labelling and hormonal treatment of ROS 17/2"8 cells.
Isotopic labelling of ROS cells was accomplished in a
microcarrier spinner flask modified with an access hole in
the polyethylene screw top. This permitted insertion of a
5 ml pipette into the stirring bead suspension for
withdrawal of experimental aliquots. Cells were labelled
with either 5,6,8,9,!1,12,14,15-[3H]arachidonic acid (AA
New England Nuclear) and/or [32p]orthophosphoric acid (NEN)
according to the conditions described in the results
section. Labelled csll samples were placed into glass tubes
and incubated for at least 30 min at 37C prior to hormonal
stimulation. For experiments examining [3HI release from
3H]AA prelabelled cells, 00 l samples were taken from
ROS-conditioned medium at designated time intervals and
counted by scintillation spectrometry.
Human
-34 PTH (generous gift of Dr. H. Keutman) was
stored at -80C as a I0-5M stock solution in 0.Z Na acetate
(pH 4.0) with mg/ml BSA (Fraction V, Sigma). For
experimental use, this stock solution as dissolved in
sufficient F-12 medium to deliver the required
total volume of 20 l. All control tubes received PI’H .
vehicle and shm manipulations. An23187 was store8 at--2.0C
as a 20 mM s’.,-k solution in absolute
Methods for lipid extraction and thin layer chromatography..
For experiments examining PTH effects on lipid
labelling, incubations were stopped with the addition of
organic solvent to the glass culture tubes holding R0S
cells. Lipids were extracted utilizing a modification of
the method of Garbus et al. (24). According to this method,
each tube containing ! ml of medium plus beads received 4 ml
of chloroform:methanol (I. :2) followed by a 10 second
sonication. After standing for 2 hr, each tube then received
1.5 ml of
(pH 7.4).
chloroform and 1.5 ml of 2M KCI with 0.5M K2PO 4
After vortexing, tubes were centrifuged for 10
minutes at 1000 x g and the aqueous phase discarded. The
lower organic phase was then transferred and dried under a
stream of N2 gas. The remaining cell pellet was then assayed
for DNA using a modification of the method of Burton (13).
Prior to TLC separation of phospholipids, an internal
standard of 5 g of phosphatidic acid (PA) was added to each
lipid sample to facilitate identification of labelled PA on
TLC plates.
Unidimensional
silica gel G plates
TLC was carried out on 0.2 m LHP-K
(I0 x 20 cm, Whatman). The following
solvent systems ,sere used: solvent system
chiorofor.:ethanol triethanola mine :H20 (’30:34:35
d solvnt system B, chloroform: pyridine:fo.ric acid
(50:30.7 v/v) (21). Solvent system A was used to ,separate
phosphatylethanolamne (PE), phospha.t dy serin’s ,..).
phosphatidylinositol (PI), and phosphatidylcho!ine (PC)";
whereas solvent system B was used to separate PA and PE from
other phospholipids. Individual lipid samples were taken up
in 20 l of chloroform, dried to 5 ul, and spotted on TLC
plates. This was followed by 4 washes of 5 ul each, spotting
each wash below the previous one. Following the separation
of phospholipids, plates were dried and sprayed with I mM 2-
p-toluidinylnap.hthylene 6-sulfonate in 50 mM Tris (pH 7.4)
and lipids visualized with UV light. Individual
phospholipids were identified by cochromatography with
authentic standards. Lipid spots were-scrapped and counts
determined using scintillation spectroscopy. Two dimensional
chromatography according te the method of Yazlhara (107) was
used to verify one dimensional TLC results.
PTH stimulation of cyclic-AMP in ROS cells.
PTH stimulation of R0S 7/2"8 cAMP was assayed for
samples taken from microcarrier culture at days 2,4,6, and 8
after inoculation. After sampling, the microcarrier beads
were allowed to settle, the culture medium was aspirated,
and the cells labelled for 2 hr in S ml of F-S2 medium
containing
[HSadenine
2 FCS, kanamycin sulfate, and S Gi/ml
(New England Nuclear). The medium was then
and the microcarrier pllet washed 3 times with
nedium Ce.,il samples were incubated for I hr in I m! of F-!2
medium containing 2% FCS and I mM isobutylmehy!xanthineo
Samples ,.ere then treated with hormone or diluent at t’e
indicated concentrations and incubated for 5 minu,es.
Reactions were
TCA. Labelled
stopped with the addition of 25 I of 25%
cAMP was then determined according to the
method of Solomon. (85).
PTH inhibition of alkaline phosphatase activity in ROS
cells.
Alkaline phosphatase activity as assayed in duplicate
control and PTH-treated samples taken from each of 3
microcarrier flasks at the indicated time points. After
sampling, the cell medium was supplemented to contain 10-9 M
PTH or diluent and the R0S 17/2"8 cultures incubated for 48
hr. Alkaline phosphatase was soiubilized with the addition
29
of 1 ml of 8o2 Triton X 100 and vortexing. A 50 l sampla
taken for assay of p-nitrophenylphosphatase activity
according to the method of Lory (52) as modified by Majeska
et al. (54). The percent of hormonal-inhibition of alkaline
phosphatase activity (corrected for DNA) was calculated for
each microcarrier flask and summed for all flasks.
Determination of DNA content in ROS cell samplehs,.
DNA was determined by colorometric assay according to a
modificationof the method of Burton (13). Cell pellets were
taken up in 2 ml of 0.SN perchloric acid and incubated for
,!5 rain ,it, 70C, vortexing frequently. Undissolved mater;ial
was then <;entrifuged and the supernatant rem,oved followed
the addition of ! ml of 0.5N perchloric acid. After a second
"15 rain h;drolysis at 70C, the undissolved
pelleted and the supernatants pooled. Fresh diphenylamine
reagent (4 ml) was then added to each of the pooled
supernatants and the Samples incubated for 18 hr at 37C.
Samples were then read at 600 nm against a standard curve of
known DNA content.
All results are expressed as the mean + standard error.
Differences between means were evaluated by the Student’s t
test as described in the results section.
Results:
Hormonal responsiveness of ROS cells grown in microcarrier
culture
MC has been utilized for the growth and maintenance of
a wide variety of substrate attached cells (!6), including
bone cells (35). The effect of this culture method on cell
properties, such as hormonal responsl.veness, has not been
established. It was therefore important to compare PTH
responsiveness of R0S 17/2"8 cells grown in microcarrier
culture with previousl characterized responses for cells
grown on conventional plasticware. Figure I shows the PTH
dose dependent stimulation of R0S 7/2"8 cAMP levels with
increasing time of growth in MC. There does not appear to be
any significant alteration in cAMP response with increasing
bime in MC. Figure 2 shows that PTH inhibition
alkaline phosphatase was highly dependent on the time
culture. As shown, maximal inhibition of ROS alkaline
phosphatse occurs for cells grown for 4-8 d. ays in
microcarrier culture.
greater inhibition of
Majeska et al. (S&),
alkaliue phosphatase
observed slightly
with 10-9M PTH,
assayed on cells grown for 7 days in conventional culture.
[3H]AA labelling of ROS phospholipids in mlcocarrler
culture
Phospholipid extractions were carried out using a
modification of the method of Garbus et a1.(24). Using this
method, a single chloroform:methanol wash
than 92 + 1.6 (3 trials) of the available
extracted greater
[3HI counts in
R0S cell samples labelled as previously described.
Presumably, all label would not be extracted from these
samples, particularly since AA does not efficiently
Figure I. stimulation of R0S 17/2"8 cyclic AMP levels by
PTH. Stimulation of cyclic AMP levels was determined for R0S
7/2"8 cells grown for 2(), 4(v), 6(e), and 8(A) days in MC
(n=4 for each point).
cp(n H -cAMP
u, DNA
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partition into organic solvent in the presence of neutral
pH-high salt aqueous solvent. Acidic conditions facilitate
the extraction of AA as well as acidic phosphollpids. An
additional chloroform:methanol wash of the cell samples
recovered only an additional 3 of the total available
counts whereas reextraction with chloroform:methanol:HC1
2:1:0.4) recovered the remaining K3HS counts
the majority of [3H]AA was incorporated into PI,
(4%) Since
PE, and PC,
the recovery of these phospholipids was assumed to be high
However, the recovery of PA was of concern because it is the
ost acid,ic of the phosphollpids and it is present in
levels in R0S 17/2"8 cells. Three extraction m,ethods
were compared in their efficiency for PA and PE extraction.
It was found that a single wash w i t,h acidic
chloroform:methanol according to the method of Billah et al.
(7), recovered significantly less [3HI labelled PE and PA
than the method of Garbus et ai.(24). In addition,
reextraction of the extracted cell samples (Garbus method)
with acidic chloroform:methanol did not recover
significantly more counts in PE and PA. All lipid
extractions in the present study, therefore, utilized the
method of Garbus et al. (24).
To examine the stability of [3H]AA labelling of ROS
phospholipids in
prelabelled with
microcarrier culture, cells were
[3H]AA for 24 hr and transferred from MC to
stationary culture in glass tubes. The time dependence of
Figure 2. Effect of I0-9M PTH on alkaline phosphatase
activity in ROS 17/2"8 cells maintained in MC. Cells were
cultured for the indicated period in MC and aliquoted into
glass tubes. Following stimulation with hormone or diluent,
cellswere cultured for 8 hr in glass tubes and harv.ested.
Alkaline phosphatase was standardized against cell DNA.
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label redistribution in ROS phosphOlipids was determined
from the point of sample transfer. Figure 3 shows the
distribution of K3HSAA in the major phospholipids of R0S
cells following removal from MC. Incubations were terminated
with the addition of organic solvent. As shown, there is
little redistribution of label following the removal of R0S
17/2"8 cells from MC. Since there was a small decrease in PE
labelling for up to 0 rain after removing cells from MC, all
subsequent experiments allo cultures to equilibrate for at
].east 0 minutes prior to stimulation with PTH.
PTH effects on 3AA release from ROS cells
Fig.re 4A demonstrates the extent of st mulation o
label, appearance in ROS 17/2"8 cell culture medium
following s-timu!.tion with PTH or A-23187, Cells were gro",’,
for 7 to 14 days :in MC, preiabelied with [3H]-AA for 24hr,
and washed with unlabelled medium immediately
aliquoting cell suspension into glass tubes. [3HI
prior to
release
was significantly increased (p<O.05) by 12 hr of PTH
treatment whereas 3 and 24 hr of hormone exposure were
without significant effect. Figure,%B depicts the release of
label from a representative cell preparation. Consistent
with the capacity of A-23187 to stimulate Ca dependent
phospholipase activity (65), the release of [3H] label from
R0S cells was markedly stimulated with A-23187 treatment.
The magnitude of the Ca ionophore effect indicates that PTH
is not a potent stimulus of this process. The PTH stimulated
Figure 3. Effect of removing R0S 17/2"8 cells from MC on
label distribution in major phospholipids. Cells were grown
for 7 days in MC and labelled only for the last 24 hr with
[3H]AA (1 ,uC+/-/lO0 ml). Al.quots of the cell suspense.on were
transferred to glass tubes at time 0 and organic solvent
added at the indicated time points. Each point represents
the mean + S,.E, for 6 trials.
approximately 1.5 x 106
Samples contained
cells / tube as determined by DNA
content.
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Figure 4. PTH stimulation of 3H] label release from 3HAA
prelabelled R0S 17/2"8 cells. Cells were grown for 7-I days
in MC and labelled for 24 hr prior to dispensing the cell
suspension. Cells were washed with unlabelled medium
immediately before cell suspension was
tubes (5 ml aliquots). [3H] appearance
transferred to glass
was quantitated by
removing 0.5 ml of culture Supernatant at the indicated time
points. Results are depicted as stimulation of [3H]
release in (A) and a representative release experiment in
(B). Results are for 10 -8 M PTH ( m ), 5 uM A-23187 (v),
ad /ehic_]..e cortrol (@). Each point in (a) represents
mean +_ w. E. _or 7 points Significant stimulatin was
observed f,r (a) I0-8M PTH at 12 hr (p<0.05) and (b) A-23187
(!0-5M) at 12 and 2 hr (p(O.O05).
T/C
Medium cpm
0.5 m|
3 12 24
IOO0
3 12 24
A
(’) ,5x 10-6M A23187
(=1) I0-8M PTH
B
release in these experiments was obserzed only when labelled
cells were washed with unlabelled medium prior to hormonal
treatment. When 24 hr prelabelled cells were stimulated
without exchanging medium, PTH had no effect on medium 3H
content (data not shown).
Table shows the distribution of 3HI and 32p label
within R0.S17/2"8 phosphollpids in control and PTH treated.
cultures at I rain and 24 hr after hormone addition. Cells
wets prelabelled for 24 hr with either 3HAA or 32pP04
prior to stimulation. The medium was not exchanged prior to
aliquoting cell samples, in an effort to maintair. .he
approp’ia.e steady state for determining PTH effects.
0-’SM or I0-10M had no significant effects on [3H] or
PTH a t
dis,tribution in ROS phospholipids. In addition, 24
exposure to PTH had no significant effect on DNA content of
R0S 17/2"8 cultures.
The increased rate of [3HI release observed following
PTH treatment of R0S cells might result from a stimulation
of phospholipid metabolism without affecting the long term
labelling of phospholipids. This process
measuring the uptake of label into
following hormonal stimulation. Figure
can be monitored by
phospholipid pools
5 presents the time
of [32p]P04 into R0S phospholipids with anddependent uptake
without PTH treatment. R0S cells maintained in MC were
labelled for 2 hr with I00 Ci [32p]P04/200 ml of F-12
medium. At that time, aliquots of cell suspension were
Tabl e
CPM/Cell Sample
Phospholipid I0-8M PTH I0-tOM PTH Control
3H-PC 5619 _+ 353 5750 _+ 234 5824 _+ 748
32p-PC 7563 + 1696 15560 + 657 16533 + 3112
3H-PI 3892 + 443 3577 + 41 3578 + 354
32p-PI 3577 _+ 4 3565 + 324 3387 Z ,323
H-PE 783S + 712 7593 + 602 7560 + 765
3:P-PE 6569 + 1069 6450 + 984 6673
DNA (ug/ce!l sample)
25.6 + 1.9 23.7 + 2.3 25.6
Table ., Effect of PTH on [3H]AA and [32p]PO 4 content of ROS
17/2"8 phospholipids Cells were grown for 6 days in MC and
labelled for 24 hr with [3H]AA ( Ci/100ml) and [32p]-PO 4
<50Ci/200ml), Without exchanging medium, labelled cell
suspension was transferred to .glass culture tubes and
treated with hormone or diluent, 3H counts were corrected
for 32p coincidence, All data are expressed as mean + S.Do
for 5 trials,
5. The effect of PTH on [32p]P04 uptake into R0SFigure
17/28 phospholipids. Cells were grown for 7 days in MC and
labelled for 2 hr with [32p]-P04 (100Ci/200ml) prior to
transferring cell suspension
cells_ube). Hormone (10-8M) (1)
0 min. Each point represents the
to glass tubes (1.5 x 106
or diluent (@) was added at
mean + S.E. for 3 trials.
(e) Conoi
(I) O’-SM PTH PC
32
cpm P
ug D,;A
120
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-10 0
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placed in glass tubes and incubations were stopped at th
.ndlcated time points. As shown, PTH treatment
significantly alter K32pSPO 4 uptake into PC, PE,
during I hr of of hormone treatment.
did no t
and P I
Although it has
induced alterations
phospholipids in ROS
not been possible to identify PTH
in [3H]AA content of the major
cells, the small increase in
release from PTH-treated ROS cells allows the possibility
that label is bsing released from quantitatively minor lipid
classes. Phosphatidic acid (PA) is generally found in ver
low levels in cells, yet rapid phosphor$lation of PA’ canbe
o,served,ithin seconds to minutes following chemical or
horizontal ,timulation of certain cell types. The follo.ing
experime,,ts examined whether PTH could promote PA
phosphorylation in ROS cells. Figure 6 shows that PTH had no
effect on [32p]PO 4 uptake into PA in ROS 17/2"8 cells nor
was there any effect on [3H]AA content in PA. Short term
[32p]PO 4 label (2 hr) was utilized to measure PA turnover
whereas long term [3H]AA label (24 hr) was thought to
reflect alterations in PA arachidonic acid content. PE
labelling was included as a reference lipid for PA
labelling.
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Figure 6. The effect of PTH on [32p]PO uptake and [3H]AA
content of phosphatidic acid in ROS 17/2"8 cells. Cells were
grown in MC for 6 days followed by 22 hr labelling with
[3H]AA (I Ci/ 100ml). The MC medium was then exchanged with
phosphate free Hanks salts and cells labelled for 2 hr
[32p]PO 4 (10 Ci/ lOOm.l).
transferred to glass tubes
stimulated with s o-SM PTH
represent the mean _+ S.E.
with
Suspension aliquots were then
(1.5 x S06 cells/tube) and cells
(m) or diluent (@). Data points
for 5 trials. PE was included as a
reference lipid.
3
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Discussion:
Microcarrier culture provides an efficient technique
for growing large numbers of substrate attached R0S 17/2"8
cells. In addition, aliquots of confluent bead suspension
demonstrated a high degree of uniformity with respect to DNA
content and label distribution in phospholipids. In these
experiments, it was also important to avoid mechanical
harvesting of cells in aqueous medium prior to organic
Solvent e.xtraction of phospholipids as this manipulation can
affect phospholipid metabolism (! 7). Cells grown on
.onventional plastic dishes must be mechanically harvesbd
prior to ,extraction of lipide since organic solvent will
dssolve ,ost plastic vessels. By aliquoting cells from
microcar’:er culture to glass tubes, it as possible
hormonally stiulate cells and extract phospholipids in the
same vessel without an intervening mechanical harvesting.
The PTH responsiveess observed for R0S 17/2"8 cells
grown in MC was comparable to that previously observed for
cells grown on conventional plasticware. The cAMP dose
response for R0S 17/2"8 cells grown in MC was virtually
identical
Maximal
to that reported for
stimulation of cAMP
cells grown on plastic (54).
levels with I0-8M PTH -was
approximately 10 fold (see figure I), somewhat less than
prevously reported (5+). However, cAMP stimulation was
evaluated several times over the course of the current study
and maximal stimulation of cAMP with I08M PTH was
subsequently found to be approximately 60 fold. The
magnitude of the cAMP response, therefore, appears to be
dependent on additional factors beyond hormone dose alone.
PTH (S0-9M) inhibition of alkaline phosphatase in ROS
cells grown for 7 days in MC was also reduced when compared
to previously reported responses observed with cells grown
for 7 days on plastic (5). However, these cultures were
assayed ,for PTH inhibition of alkaline phosphatase at the
same time that reduced cAMP responses were observed. No
additional asaays were attempted to determine whether PTH
.mhibitlon. of alkaline phosphatase varied as widely as cAMP
responses to a given dose of horzone. To our know].edg
’these results are the first to demonstrate hormonal
r.sponsive.ness of osteoblast-like cells growr iu C.
The appearance of [3HI in medium conditioned by [3H]AA
labelled R0S 17/2"8 cells treated with A-23187 reflscted the
capacity of microcarrier grown cells to release
preincorporated arachidonic acid. Relative to the A-23187
effect, PTH had only a slight effect on [3H] release. PTH
was found, to stimulate the re!ease of [3HI only when
labelled cells received fresh medium immediately prior to
hormonal stimulation. The increased release of [3HI in these
experients presumably represents a more rapid rate of tracer
release from PTH treated cells. However, cells which did not
receive fresh medium demonstrated no increased release of
[H] label into the surrounding medium after 24 hr PTH
treatment (data not shown). These results suggest that a net
release of EHS label from R0S
PTH effects on label release.
cells is required to observe
Interestingly, 3HS levels in
R0S 17/2"8 conditioned medium were identical after 2 hr of
culture regardless of whether cells were maintained in MC or
in glass tubes (data not shown). Stimulated release of K3HS
following treatment with A 23187 indicates that R0S cells
possess the capacity to release increased amounts of AA with
appropriate stimuli. However,
in K3HS release folloing PTH
the relatively small
treatment suggests
increase
that this
hormone is not. important in this process.
Attempts to identify alterations in [3H]AA contert of
phospholipids in R0S i7/2"8 cells following PTH treatment
iolded negatAve results These experiments examined []
content of R0S phospholipids for up to 24 hr of PTH
exposure. Label incorporation into major phosphoiipids after
2 hr exposure to [3H]AA was unchanged after an additional
24 hr incubation with I0-8M PTH. These results indicate that
PTH does not selectively transfer AA from or between the
major phospholipids in ROS 17/2"8cells. That phospholipid
metabolism was not affected by 24 hr exposure to PTH was
supported by experiments utilizing [32pIP04 asalso tracer.
R0S 17/2"8 cells were labelled for 24 hr with [32p]p04
according to the scheme described for [3H]AA labelling. It
that [32pIP0 4 content of majorWaS demonstrated
phospholipids in R0S cells remained virtually unchanged for
2& hr control and. PTH treated cultures. In summary, PTH
treatment was without effect on [3H]AA release from major
phospholipids in ROS cells and was unab-le to alter [32p]PO/,
labelling of phospholipids.
PTH-stimulated release of label into Roe 17/2"8
conditioned medium might be a manifestation of altered AA
metabolism resulting from increased phospholipid turnover.
Enhanced AA release has been directly associated with
stimulation of phospholipid turnover in a variety of cell
types following stimulation with cell, specific hormones or
certain chemical agents (34,93).
labelling consistent Tith increased
Generally,
turr.over
e t aboli c
observed
within seccnds to minutes following cell stimulation and is
liited to, certain phospholipid metabolic path,as. Two
major pathways have been identified to date: I) sequential
methylation of PE to PC with subsequent release of fatty
acid from PC (31) and 2) rapid breakdown of PI and
polyphosphoinositols (DPI and TPI) to diglyceride with
subsequent synthesis of PA and/or release of fatty acid from
diglyceride (04). In dog kidney slices, [32p]PO
incorporation into PI, TPI, DPI, and PA is stimulated within
5 minutes of PTH treatment in a manner consistent with
increased phospholipid turnover (58). In the
PTH was shown to have no effect on [32p]PO4
present study,
uptake into PI,
PC, and PE for up to 60 minutes of hormone exposure.
Additional experiments also demonstrated that PA labelling
in ROS 17/2"8 cells was unaffected by PTH treatment. These
findings, therefore, indicate that PTH does not stimulate
phospholipld turnover in R0S cells in a manner comparable to
that previously observed in another PTH target tissue, the
kidney.
In conclusion, the results of the present study
indicats that PTH do,es not sufficiently affect the
metabolism of 3HS-AA in R0S cells to be considered an
important factor in endogenous AA metabolism in this cell
type. The apparent capacity of R0S 7/2"8 cells to release
signiflcart quantities of PGE2 may relat to unusually i,_g
basa. 1 phospholipid turnover (69) althouho th possibility
that exogenous AA is
proluction cannot be
the predominant substrate in FGE 2
excluded. In ay cas,
s,nd phospholipid metabolism does not appear to be regulated
by PTH such that increased production of PGE 2 #ould result
from release of AA from endogenous esterified AA sources.
This does not exclude the possibility that PTH may affect
phospholipid metabolism and AA release in non-transformed
osteoblasts or in another subgroup of osteoblastic clonal
cells.
Chapter 2.
C3b and LPS stimulated release of PGE and TXB 2 from human
morlonuclear phagocytes in culture: Evidence for independent
conversion of arachidonic acid to PGE2 and TXB2o
Abstract:
v3b treatment of human peripheral blood mononuclear
phagocytes (HMP) in culture stimulates an early release of
thromboxane B2
E (PGE) into
(TXB2) and a delayed release of prostaglandin
culture supernatants. We examined C3b
stimulated eicosanoid production in 3H-arachidonic acid (AA)
prelabelled HMP by comparing the time course of 3H release
from HMP.phospholipids with the appearance of H-labelled
PGE2, TXB2, and AA in culture supernatantso In addition, we
compared the time course of immunoreactive PGE and TXB2
rslease with radio.abelled PGE2 and TXB 2. Identification and
quantitation of radiolabelled AA metabolites was performed
by TLC and results were corroborated by high pressure !iquAd
clromatography (HPLC). Following C3b treatment of HMP the
time course of radio!abei!ed TXB 2 release was found to be
conparable to TXB 2 measured by radioimmnoassay (RA). In
addition, the stimulated release of" 3H label from HMP
phosphoiipids corresponded o the appearance of labelled
TXB 2. However, radiolabelled PGE 2 release was maximally
stimulated by 8 hr of C3b treatment whereas immunoreactive
PGE release was maximally stimulated after 1 6 hr of
treatment. In addition, stimulated release of [3H]AA into
culture supernatants was observed prior to any detectable
increas=d release of lab lied TXB 2 or PGE 2. he apparent
differential release of immunoreactive PGE vs JH-labelled
PGE2 from C3b treated HMP was further examined by measuring
HMP eicosanoid release following treatment with bacterial
lipopolysaccharide (LPS). It was found that LPS did not
stimulate labelled PGE2 release from HMP but significantly
stimulated release of immunoprecipitable PGE after 8 hr of
treatment. As with C3b stimulation of HMP, the appearance of
[3H]AA in HMP culture supernatants did not parallel labelled
TXB 2 or PGE2 release following stimulation with LPS. These
results are consistent with independent metabolism of TXB2
and PGE 2 in stimulated HMP and suggest a complex
relationship between AA metabolism and TXB 2 and PGE 2
production in HMP.
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Introduction:
Monocytes and macrophages (MP) have been shown to
release significant quantities of arachidonic acid (AA)
metabolites following stimulation with C3b cleavage
++fragments (72), antigen-antibody complexes (63), Ca
ionophore, A-23187 (I06), concanavalin A (3), LPS (75),
zymosan (02), phorbol myristate acetate (37), and other
factors (38). To date, the principal metabolites shown to be
released by the MP include TXB2,
stable breakdown product of PGI1),
and HETES (82). Although there is
PGE2 6-keto PGFI (th_e
PGFI, leukotrienes (10),
considerable variation in
the production of these eicosanoids from MP preparations
(82,23,6), the production and release of AA metab,olites i.s
thought to be limited by the availability of free AA to
cyclooxygenase and lipoxygenase enzyme systems (86). Since
free AA is normally restricted to very low levels within
cells, the regulation of AA release from cellular lipid
stores appears to determine the rate of AA metabolite
production. Two mechanisms have been reported which account
for increased free AA levels in stimulated macrophages.
These are 1) increased release of AA from phospholipids
primarily through the action of phospholipase A 2 (100) and
2) decreased reacylation of AA into lipid pools (5). AA
constitutes 20% of the esterified fatty acid in rabbit MP
(57) and in human monocytes (87). In addition, labelling
experiments demonstrate that AA is selectively incorporated
into phosphatidylcholine (PC), phosphatidylinositol (PI),
and phosphatidylethanolamine (PE) in rodent MP (83) and that
rapid turnover of these phospholipids is accompanied by
selective AA release following stimulation with certain
fac_tors (80). Although stimulated AA metabolite production
appears to be consistent with enhanced AA release from MP
phospholipid stores, direct correlation of the time course
of AA release from MP phospholipids with the appearance of
eicosanoid pro-ducts has not been established.
Increased
observed ,from
immunoreactive PGE and TXB 2 release has been
human mononuclear phagocytes (HMP) maintain.ed
in culture for 2 hr in the presence on C3b, iC3b, C3c (72),
endotoxin (LPS) (80), and antigen-antibody complexes (73).
These studies were unique in that highly enriched HMP
first obtained from freshly drawn blood through the use of
counterflow centrifugation (CC) (74). This technique permits
rapid enrichment of HMP in suspension, thus avoiding
selective adherence in mixed culture which is the most
frequently used technique to isolate MP. Utilizing CC
separated HMP, it was shown that 24 hr cultures exposed to
C3b demonstrated decreased PI levels and increased
lysophosphatidylcholine (LPC) and sphingomyelin levels when
compared to control cultures (42). Although these findings
support the proposed relationship between AA release from
lipid stores and subsequent conversion to eicosanoid
products, there is no direct evidence demonstrating release
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of preesterified AA in C3b stimulated HMP and subsequent
conversion of released AA to eicosanoid products. We report
here experiments which examine this relationship in C3b
treated HMP by comparing the time course of labelled AA
release and conversion to metabolites with the release of
immunoreactive eicosanoids. In addition, labelled metabolite
release was examined afte.rtreating HMP with LPS.
Materials and Methods:
Materials. K3HSArachidonic acid (87 Ci/mmole),
(113 Ci/mmole), and [3HSPGE2 (165 Ci/mmole) were purchased
from New England Nuclear. Phospholipid standards were
obtained from Supelco. Arachidonic acid, TXB2, PGE 2, 2-p-
toluidinylnaphthylene 6-sulfonate (TNS), penicillin ant
streptomycin were obtained from Sigma Chemical Co. MCDB 104
was purchased from Flow Laboratories. Anti-PGE 2 antibody
(generous gift of Dr. Lole) and anti-TXB2 antibody (Seragen)
were used for radio+/-mmunoassay. Fetal calf serum (FCS) was
obtained from Hyclone Laboratories. C3b was prepared by by
mild tryptic cleavage of purified C3 and separated from C3a
by gel filtration on Sephadex G-75 or Sephacryl $200 at pH
4.5 (72). Preparations were assessed for purity and
characteristic antigenicity by immunoelectrophoresis and
SDS-polyacrylami’de gel electrophoresis. Purified proteins
were
pore
dialyzed against PBS, pH 7.5, and passed through 0.45m
filters prior to being used in culture. LPS (Salmonella
typhimurium) was purchased from Calbiochem-Behring.
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Cell isolation and culture. Human monocytes were
isolated by counterflow centrifugation (CC) as previuosly
described (7). Briefly, citrated fresh human blood,
obtained by venipuncture, was separated by ficoll-Hypaque
density gradient centrifugation to yield a highly enriched
mononuclear cell fraction. This cell fraction was then
subjected to CC during which platelet and lymphocyte elution
was monitored by electronic sizing of effluent cells from CC
(Coulter ZM-counter, Coulter Electronics, Hialeah, FL). Once
the monocyte fraction had been sufficiently enriched,
centrifugation was terminated and monocytes quickly eluted
from the separating chamber. Monocytes were then pelleted in
Ca-Mg free PBS with I autologous citrated plasma and
resuspended in appropriate medium for culture inoculation.
The cells were resuspended in a known volume of MCDB
!04 containing IZ FCS, 100 U/ml penicillin, and I00 mcg/ml
streptomycin, and monocyte recovery determined by electronic
counting. The cell
concentration of
suspension was then diluted to achieve a
1.0-1.3 x 106 cells/ml and I ml aliquots
were placed in glass wells (18 mm diameter). For experiments
evaluating labelled AA metabolism, [3H]AA was added to the
monocyte suspension at 0.1 Ci/ml and cells inoculated at
the same density. All cultures were then incubated at 37C
for 2 hr in a humidified atmosphere of 5 CO 2 in air after
which the cultures were washed 2 times to eliminate
unincorporated label and/or nonadherent cells. Cultures were
6O
then treated with media containing C3b (15 ug/ml) or LPS (10
ug/ml) vs control medium.
At 2 8 16 and 24 hr, the cell-conditioned medium (CM)
was replaced with identical fresh-medium and the CM
centrifuged at 2500 x g for 5 mino Supernatants were then
stored frozen under N2 in sealed glass tubes until analyzed
by RIA for PGE and TXB 2. In the case of labelled cultures,
medium was
supernatant
exchanged at identical time points and 100 ul of
counted to determine [3HI release. The remaining
supernatant was stored as described above until extraction
of labelled AA metabolites.
RIA for PGE and TXB2. Immunoreactive PGE present in the
culture supernatants was determined by radioimmunoassay
using ammonium sulfate precipitation of monoclonal anti-PGE2
antibody. PGE content of culture supernatants was
extrapolated from logit-log PGE2 standard binding with each
assay (detection limit of 100 pg/ml). PGE 2 stock solution
was diluted in Tris buffer (10raM Tris, I0 mM NaC1. pH 7.6
with 2 mg/ml human gamma globulin) to give dilutions of 100
to 50,000 pg/ml. Anti-PGE 2 stock solution was prepared by
diluting 20 l monoclonal antibody stock in I ml of Tris-
gamma globulin buffer. PGE content was then determined by
[3H]PGE 2 counts remaining in the assay supernatant after
ammonium sulfate precipition. All determinations were
carried out in duplicate and the average counts for each
pair used to calculate PGE content. Regression coefficients
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of logit-log standard curves were generally greater than
0.990.
Absorption by activated charcoal rather than
immunoprecipitation was used to determine TXB2 by RIA. All
solutions were prepared in Tris buffer (SOmM Tris, 140mM
NaC1, pH 7.4, with 0. gelatin). Anti-TXB 2 stock solution
was prepared by diluting 1 vial of antibody (Seragen) in 20
ml of Tris-gelatin buffer. Generally, 10 l of culture
supernatant was assayed for TXB2 content. TXB2 content was
determined by supernatant [3H]TXB 2 counts remaining after
Norlt-A absorption of
commercially available
unbound TXB 2
kit (Seragen).
according to a
The TXB 2 standard
curve and unknowns were calculaJted by logit-log
transformation and linear regression as with PGE RIA.
Labelled arachidonic acid metabolite extraction and
separation. AA metabolites were extracted by first adjusting
the pH of culture supernatants to 3.0 with formic acid (70)
followed by two 3ml washes with ethyl acetate. The combined
organic extracts were evaporated under vacuum and stored at
-20C under N2. Prior to TLC separation of AA metabolites,
AA (5g), TXB 2 (5g), and PGE 2 (5g) were added to each
sample and the contents dried under a stream of N 2.
Individual samples were dissolved in I01 of chloroform,
vortexed, and spotted on LHP-K plates (precoated 200 m
silica gel G, Whatman). This was followed by 3 additional
washes with 5 i of chloroform, spotting each wash
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immediately below the previous application. Plates were then
developed in I dimension with chloroform:methanol:acetic
acid:H20 (90:8:1:0.8 v/v) (98). After drying, the plates
were sprayed with fluorescent indicator (I TNS in 50 mM
Tris, pH 7.4) and lipid spots visualized with UV light. AA
metabolites were identified by comigration with authentic
standards after which spots wer.e scraped and counts
determined.
Phospholipid extraction and separation. Phospholipids
were extracted directly from glass wells using a
modification of the method of Billah et al. (8). Briefly,
wells were washed 4 times with 0.5 ml of
chloroform:methanol:HC1 (10:20:1 v/v) after which fewer than
100 cpm could be recovered from any well. The pooled organic
extracts from individual wells were then brought to 4 ml
with the same extraction solvent followed by the addition of
1.2 ml of 2 M KC1 and 1.2 ml of chloroform. The samples were
vortexed and centrifuged for 5 min at 1500 x g to facilitate
phase separation. The upper phase was discarded and the
lower organic phase transferred to Reacti-vials and dried
under a stream of N 2. The extraction efficiency of this
method was found to be virtually identical to the neutral
pH-high salt extraction procedure of Garbus et al. (24).
Phospholipids were separated by 1 dimensional TLC
employing the following solvent system, chloroform:ethan-
ol:triethylamine:H20 (30:34:35:8 v/v) (95). One dimensional
phospholipid separations were used as a preliminary means to
identify alterations in 3HIAA content of phospholipids. For
this separation, lipids Were dissolved in
chloroform, vortexed, and spotted on LHP-K plates (precoated
200 m
washed
silica gel G, Whatman). The sample vial
times with 5 l of chloroform, spotting
was then
each wash
immediately below the previous application. The plates were
then developed and lipids visualized with Z TNS (see
above). Individual lipids were identified by comigration
with authentic standards and counts determined by scraping
spots.
Results:
Release of radiolabel in culture medium by HMP
prelabelled with [3H]AA. Figure 1 shows the effect of C3b on
appearance, in medium equilibrated with HMP monolayers
attached
diameter,
to both glass and plastic culture wells (16 mm
Falcon). HMP were labelled with [3H]AA for 2 hr
and washed free of any unincorporated label prior to
stimulation. Plastic and glass cultureware were compared
because previous investigations of C3b effects on HMP
eicosanoid release have utilized cells attached to plastic
dishes only (72,80,73). The use of glass wells facilitated
direct organic extraction of cellular phospholipids which
was not possible with plastic culture ware. As can be seen,
comparable [3HI release was observed for HMP cultures
adherent to glass and plastic. It should be emphasized that
Figure I. Comparison of time dependent K3HI release from
control or C3b treated HMP cells attached to glass or
plastic culture wells. Culture supernatants were obtained by
centrifuging HMP conditioned medium at 2500 x g for 5 rain.
Each determination represents the mean +_ S.E. for
trials. The release values are for plastic wells with either
control medium ()or 15 ug/ml C3b (S) and for glass
wells with either control medium () or 5 ug/ml C3b
(). All subsequent experiments utilize HMP attached to
glass dishes only.
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Figure 2. C3b dose dependent 3HI release from HMP
culture. Control (E) release represents the mean +_ S.E.
for 8 trials. For all other determinations, n=.
concentrations ere as follows: 0.05 )g/ml (),
g/ml,(U), 1.5 g/ml ( ), and 15 g/ml ( ).
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doses of C3b also did not stimulate release of K3HS over
control cultures.
Effects of C3b on [3H]-phospholipid content. Figure 3
demonstrates the time dependent alterations in [3H]AA label
within HMP lipid classes with and without C3bstimulation.
As shown, C3b reduced the label within PI and PC without
affecting labelling of PEo C3b increased therate of K3HS
label clearance from PC and PI for up to 8 hr of stimulation
afte which label clearance was reduced to that seen in
control cultures. It was also interesting that lipids
migrating at the
lipids, increased
solvent front (Unk.), presumably neutral
[3HI content between 2 and 8 hr after C3b
stimulation. This increase coincided with the maximal
decrease in PI and PC labelling following C3b stimulation.
+/-n these experiments, lipids were separated by I
dimensional TLC (see methods) as a preliminary evaluation of
of alterations in label distribution. Definitive studies are
now in progress to confirm these results by 2 dimensional
TLC and to extend this study
turnover events in association
to identify phospholipid
with alterations in [3H]
label distribution following C3b treatment.
The data in Figure 3 also demonstrate the time
dependent redistribution of label between lipid classes
within control or C3b stimulated HMP. These results indicate
that 2 hr exposure to exogenous [3H]AA resulted in label
incorporation primarily into PI, PC, and presumably neutral
7O
Figure 3. Effect of C3b on K3HS label content of selected
HMP lipids. Each point represents the mean +_ S.E. for 3
trials. With the exception of lipids migrating at the
solvent front (Unk.), phosphatidylethanolamine (PE),
phosphatidylcholine (PC), and phosphatidylinositol (PI) were
identified by comigration with authentic standards. Data
points represent control medium (@) and 5 g/ml C3b ( I ).
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absence of exogenous
to this initial uptake, and in the
3H]AA, label was redistributed from
PI, PC, and neutral lipids into PE and other lipids with
increasing time in culture. This phenomenon was also
suggested by the label distribution observed in HMP lipids
following 2 or 26 hour exposure
3HAA. PI and PC demonstrated
(approximately 25) in [3HI content
exposure to
to identical amounts of
only modest increae
with an additional 2 hr
3H]AA whereas PE and PS demonstrated greater
than mfold increased labelling between 2 and 2/+ hr in
culture (data not shown).
C3b and LPS stimulated release of PGE and TX. 2
determined
-s RIAo Figure % shows the effect of C3b (i.5
xg/mi) on TX2 and PGE release from HMP cultures derived
from 2 donors. As with [3H] release from HMP cultures, the
release of AA metabolites was cumulative over the indicated
time interval The time course of TXB 2 release was
considerably different from PGE release. When metabolite
release was expressed in ng/hr, TXB2 release demonstrated a
maximal rate during the 2-8 hr time interval whereas PGE
release was maximal after 16 hr of C3b stimulation.
Figure 5 demonstrates the effect of LPS and C3b on PGE
release from HMP cultures prepared from the same donor. The
release of PGE from HMP control cultures in this preparation
was appreciable, in -contrast to the control release in
Figure 5. Conversely, C3b-stimulated release of PGE was
Figure . Time course of TXB 2 and PGE release from HM
following stimulation with C3b (15 #g/ml). Each value
represents the mean +_ S.E. for 6 trials for TXB 2 () and
(). Values represent the average response for HMPPGE
isolated from 2 donors. TXB2 release from control cultures
did not exceed I ng/ml and PGE release from controls did not
xceed 0.1 ng/ml.
IOO
8o
"t
-
ng F__3 2 60
4O
ng PGE
ml
0-2 2-8 8-16 16-24
Houm,
Figure 5. PGE release from HMP cultures stimulated with C3b
or LPS. Each point represents the mean + S.E. for 6
trials. HMP were isolated from the same donor. The release
values are for control medium (), 10 g/ml LPS (), and
15 g/ml C3b ().
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comparable to that observed in Figure 4. A previous report
has also noted considerable variation in the stimulated and
control levels of PGE and TXB 2 released by cells from
different donors (72). Cultures stimulated with LPS (I0
rg/ml)demonstrate maximal release of PGE during the 2-8 hr
time interval, considerably earlier than was observed with
C3b. However, C3b treated cultures appeared to achieve the
same rate of PGE release as the LPS-treated cultures by 2
hr. No TXB 2 RIA was carried out on these samples. Whether
C3b and LPS mediate different effects on HMP eicosanoid
production will be the subject of future studies.
Determination of labelled AA, TXB2, and PGE2 levels in
HMP culture supernatamts. Figure 6 shows the time dependence
of labelled AA ,TXB2, and PGE 2 release from HMP cultures
following stimulation with C3b. As in previous experiments,
the metabolite release was cumulative only for the indicated
time interval. Stimulated release of K3HSAA was observed for
up to 8 hr after C3b treatment followed by a return to
control release levels. In contrast, K3HSTXB2 and K3HPGE 2
release was not stimulated during the initial 2 hr interval
after C3b treatment but was maximally stimulated during the
2-8 hr interval. In addition, continued stimulation of
labelled TXB2 and PGE2 release was observed for the 8-16 hr
interval. Also noteworthy was the similar pattern of
labelled metabolite release between TXB 2 and PGE 2 whereas
TXB 2 and PGE release determined by RIA were found to be
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Figure 6. Effect of C3b on 3H] labelled AA,
release from HMP. Each value reprasents the
TXB 2, and PGE 2
mean + S.E. for
3 trials. The values represent labelled metabolite
for control medium (-]). and 15 g/ml C3b ().
release
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considerably different
significant C3b effects
(see Figure 4). In addition, the
on labelled metabolite release have
been corroborated by HPLC analysis of conditioned medium
extracts from parallel experiments. A complete report of the
HPLC results is in preparation.
LPS stimulation of K3HSAA labelled HMP in culture gave
a similar pattern of labelled metabolite release. Figure 7
shows the time dependent release of labelled AA, TXB2, and
PGE2 from HMP cultures stimulated with LPS
used in this experiment were the same as those used in
Figure 5. As shown, labelled AA release was stimulated
during the 0-2 hr interval of LPS stimulation but returned
to control values thereafter. Labelled TXB 2 and PGE2 release
were not stimulated for up to 2 hr. Labelled TXB 2 release
was maximally stimulated during the 2-8 hr interval and
subsequently returned to control levels. In contrast to C3b-
stimulated metabolite release, significant release of
labelled PGE2 was not observed after stimulation with LPS.
Figure 7. Effect of LPS on 3H labelled AA, TXB 2, and PGE 2
release from HMP. Each value represents the mean + S.E. for
trials. Metabolite release was
edlum ( ) and I0 g/ml LPS ().
determined for control
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Discussion:
The time interval assessment of radioisotope release
from K3HSAA labelled HMP served to identify intervals of
varying metabolite release. Although the time intervals
described in this report were empirically developed from
experimental trials, they were intended to address the
previously reported differential rates of PGE and TXB 2
release observed from C3b stimulated HMP (80). The
desirability of breaking the stimulation period into several
intervals relates to the nature of the metabolite release.
As has been observed in several reports, cumulative AA
metabolite release from stimulated macrophages and monocytes
typically demonstrates a rapid initial release which tends
to plateau with increasing time of stimulation. Hoever,
calculation of the average rates of metabolite production
becomes less precise when approaching the plateau region of
cumulative metabolite release. Yet, this is the time period
where differential TXB 2 and PGE release has been observed
from C3b-stimulated HMP (80). By exchanging medium at
discrete intervals, it was possible to obtain a more
sensitive measure of average rates of metabolite release
during the attenuated response period. This approach assumes
that metabolite production during the early time periods
does not alter subsequent metabolic events. However, as will
be shown, comparison of our results with previous findings
demonstrates that our experimental design does not
discernably affect the biological response previously
characterized for HMP.
According to this construct, it was possible to
identify four intervals demonstrating different average
rates of radioisotope release following C3b stimulation of
HMP. These intervals were as follows: 0-2 hr interval of
increasing label release, 2-8 hr interval of maximal label
release, and 8-6 and $6-2 hr intervals of decreasing label
release. With some experiments, the 0-2 hr and 2-8 hr
intervals demonstrated approximately the same average
responses, when expressed as
stimulation of K3HSAA labelled HMP
cpm released/hr. LPS
produced a very simi:ar
pattern of radioisotope release to that observed
stimulated HMP. However, C3b did not
in C3 b
stimulate [3HI release
in this same HMP cell preparation. Previously, it was shown
that HMP prepared from fresh blood demonstrate a time-
dependent loss of C3b-stimulated PGE-and TXB 2 release that
was not correlated with a decrease in C3b receptor-bearing
cell numbers (79). The loss of C3b responsiveness observed
with aged buffy coat HMP may represent the same process
since these cells were obtained approximately 24 hr prior to
HMP separation and culture. Future studies will address this
question.
[3H]AA incorporation into HMP phospholipids was
comparable to that observed previously in rodent
(83,64). [3H]-AA was incorporated primarily into
macrophages
PC after 2
hr exposure whereas exposure to K3HSAA for 26 hr resulted in
much greater percentage of label incorporated into PE (data
not shown). The tlme-dependent redistribution of label in
HMP observed as a net loss of label from PC and PI and a net
increase of label
macrophages (83).
in PE, has also been observed in mouse
C3b-stimulated K3HS label release from PC
and PI without affecting PE label content is in_general
agreement with previous reports demonstrating zymosan and f-
met-leu-phe stimulated label release from PI and PC in
rodent macrophages prelabelled with K3HAA (I06,6). Also
noteworthy is the recent report demonstrating decreased PI
and increasing LPC and sphingomyelin levels in HMP treated
with C3b (42). Taken together with the present findings, it
appears that decreased 3HS label in PI may reflect
increased breakdown of PI whereas decreased label in PC may
reflect increased turnover of PC without a net breakdown of
this phospholipid. Experiments
evaluate these possibilities. The
are now in progress to
observed transfer of
label into lipids migrating at the solvent front suggests
that neutral lipids accumulate label following C3b
stimulation of HMP.
Bonney et al. (64),
This is consistenlt with the report of
where a net transfer of [3HI label into
triglycerides
[3HI AA-labelled
was observed with
mouse macrophages.
zymosan stimulation of
These results therefore
indicate that medium exchanges at the described intervals
do not adversely affect [3HI label release from HMP lipid
pools. C3b-stimulated release of PGE and TXB2 from HMP in
this study is in general agreement with previous reports.
Schenkeln and Rutherford demonstrated that maximal
stimulation of PGE release occured 20-24 hr after C3b
treatment of HMP with little or no release during the first
4 hr of stimulation (80). In contrast, TXB 2 release was
stimulated by I hr and appeared to be approximately linear
over the 24 hr exposure to C3b (80). These results were
established for HMP treated with C3b at the time of culture
inoculation and for culture medium containing 1 FCS. In
agreement with the results of Schenkein et al. (72,80), we
observed maximal PGE release during the 6.-24 hr interval
after C3b stimulation. Our results differ only in that ,e
observed a time dependent increase in the rate of PGE
release hich was detectable during the initial 2 hr
exposure to C3b.
The apparent differences in the time course of TXB2 and
PGE release from stimulated HMP suggest either selective
regulation of eicosanoid metabolism or that immunoreactive
PGE is predominantly PGE 1. The latter possibility is
unlikely since the fatty acid composition of human monocytes
has been shown to include 20Z arachidonic acid (87) with no
significant levels of linolenic acid (87,64), the precursor
fatty acid for dihomo-g-linolenic acid (DHL). DHL is
converted to PGE I by way of cyclo-oxygenaseo Mouse
peritoneal macrophages have been shown to synthesize PGE 1
when prelabelled for 4 hr with 3HSeicosatrienoic acid (DHL)
and stimulated
experiments using
with zymosan (11). However, parallel
[3HSAA as label demonstrated PGE2 as the
predominant PGE metabolite released from zymosan treated
mouse MP (29). In our experiments, the possibility exists
that fetal calf serum provided significant amounts of
linolenic acid and/or DHL which was converted to PGE I by
stimulated HMP. Deletion of fetal calf serum from HMP
culture medium would therefore be expected to reduce PGE
release without affecting TXB 2. However, PGE and TXB 2
release from C3b stimulated HMP were equally diminished
(approximately .$0%) with the removal of fetal calf serum
from culture medium (80). Because PGE release was not
selectively and substantially diminished under these
conditions, these results suggest that fetal calf serum is
not promoting PGE I production in stimulated HMP.
The time course of immunoprecipitable TXB 2 and PGE
release from C3b-stimulated HMP suggests regulation of AA
metabolism so that TXB 2 is produced earlier than PGE. This
could result from enzyme regulation which preferentially
catalyzes AA conversion to TXB 2 during early time periods
followed by a subsequent increase in the conversion of AA to
PGE 2. This possibility was examined by measuring the time
course of radiolabelled AA conversion to TXB 2 and PGE 2 in
C3b stimulated HMP. It was found that labelled and
immunoprecipitable TXB2 release were very similar whereas
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the release of labelled PGE did not parallel the release of
immunoprecipitable PGE. Assuming that +/-mmunopreclpitable PGE
represents primarily PGE2, these results indicate that the
specific activity of PGE2, expressed in cpm/ng (see Figures
. and 6), declined over the 2/. hour stimulation period while
the specific activity of TXB2 remained virtually unchanged.
Becaus.e .cyclo-oxygenase conversion of AA to PGG2 serves as
the single common pathway for the production of TXB 2 and
PGE2, these results are inconsistent with a time dependent
shift in enzymatic production from TXB 2 initially to PGE 2
subsequently. Instead, these results suggest that C3b and
LPS stimulated HMP synthesize TXB 2 and PGE2 from independent
cell sources of AA. The LPS effects were included in this
manuscript because they demonstrated the same basic patt6rn
of labelled and immunoprecipitable metabolite release as was
demonstrated by C3b. That independent metabolism of AA can
occur in C3b- and LPS-stimulated HMP is also suggested by
the early release of labelled AA into culture supernatants
without the appearance of labelled metabolites. In addition,
the time course of label disappearance from phospholipids of
C3b-treated HMP correlated only with the appearance of
labelled TXB 2. A similar increase in label release was not
observed during the period of maximal PGE release from C3b-
stimulated HMP. It is possible that longer labelling periods
with K3HSAA are required to label the requisite lipid pools
in HMP to observe parallel release of labelled and
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immunopreclpitable PGE2.
The possibility of independent AA metabolite production
has been suggested in other reports. Using elicited and
resident mouse peritoneal macrophages, Scott et al. (82)
demonstrated that AA incorporation into lipid pools can be
independent of synthesis of AA metabolites. Goldyne and
Stobo extended this observation by demonstrating that
exogenous K I4CSAA previously released by T cells could be
converted to TXB 2 in human macrophages (28). However, no
labelled PGE2 was detected in the same culture medium even
in the presence of elevated immunoprecipitable PGE release.
Because PGE levels were 15-20 of TXB 2 levels by RIA, itwas
suspected that [’i/,C]PGE2 counts would be indistinguishable
from background counts in the chromatographic separation.
Our studies suggest that Goldyne and Stobo did not observe
labelled PGE2 release because SCSAA had not equilibrated
into the requisite metabolic compartment for conversion to
PGE 2. Studies are now in progress to examine the AA lipid
pools in HMP which give rise to PGE2 and TXB2.
Thesis Discussion:
The previously described studies compare arachidonic
acid (AA) metabolism in two different cell types following
treatment with respective soluble agents known to elicit
biological responses. The osteoblast-like clonal cells, ROS
7/2"8, demonstrate little if any capacity to alter
phospholipid-AA metabolism when stimulated with PTH.
Conversely, human mononuclear phagocytes (HMP) _n xi__tro_
exhibit pronounced alterations in phospholipid AA metabolism
when stimulated with C3b. The variability in responsiveness
demonstrated in the present study is not inconsistent with
responses noted in other cells. Some hormones have been
shown to be without effect on phospholipid or AA metabolism
in their respective target tissues, i.e., glucagon.
Conversely, very pronounced alterations in phospholipid
metabolism and increased AA release have been observed in
hormonally or chemically stimulated cells, particularly
white blood cells. The variation in cell responses observed
in the present study were therefore not entirely unexpected.
The lack of PTH effects on ROS cell phospholipid-AA
metabolism was in contrast to PTH stimulation of cAMP levels
and inhibition of alkaline phosphatase activity. These
findings indicate that ROS cells express osteoblast-like
responsiveness to PTH when grown in microcarrier culture.
The lack of PTH effects on phospholipid-AA metabolism in ROS
cells grown in microcarrier culture contrasted with the
9O
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previously reported effects of PTH on phospholipid
metabolism in kidney (5). In addition to physiological
regulation of Ca and P04
regulate Ca reabsorptlon
thus, kidney is another
release from bone, PTH acts to
and P0 clearance from kidney;
important target tissue for PTH
action. Stimulation of dog kidney with PTH has been shown to
decrease PI levels, increase labelled P04 uptake into PI and
PA, and to increase prostaglandin synthesis (5). Although
ROS cells and kidney demonstrate two extremes of PTH
responsiveness with respect to phospholipid-AA metabolism,
variation in tissue responsiveness of this magn_tude has
been observed with other chemical agents. For example,-
adrenergic stimulation of cerebral cortex is without effect
on phospholipid metabolism whereas treatment of other
tissues, including vas differens,
can produce significant alterations
with 2-adrenergic agents
in phospholipid turnover
(60)o The effects of PTH on R0S cells observed in the
present study are therefore not unique.
The ability of ROS 17/2"8 cells to produce PGE2 in
culture is a perplexing issue. Particularly noteworthy is
the capacity of PGE2 to stimulate osteoclastic-mediated bone
resorption n_
_vi__tr__o and in _vi_v (,78). However, PTH-
stimulated osteoclastic resorp.tion in organ culture has been
shown to be independent of prostaglandin release (51,66).
The observed release of PGE2 from R0S 17/2"8 cells indicates
the presence of cyclo-oxygenase enzyme activity. However, it
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does not explain the source of AA for conversion to PGE2. It
is possible that AA present in the culture medium served as
substrate for the production of PGE 2. This possibility
appears likely since labelled PGE 2 release from ROS 1’//2"8
cells was greatest during the initial 2 hour period of
exposure to KI4CSAA (7). Presumably, the rate of PGE 2
release diminished due to the uptake of exogenous AA into
ROS lipids thereby reducing labelled AA availability to
cyclo-oxygenase enzyme systems. It is also possible that
KI%HSAA may transiently label a lipid/phospholipid in ROS
cells which turns over rapidly and provides free AA for
conversion to PGE 2. However, AA labeling of OS
phospholip.ids has not confirmed the presence of transient
phospholipid labeling. In summary, it is uncertain how ROS
cells regulate AA metabolism such that basal production of
PGE2 occurs at a significant rate.
The microcarrier culture system used in the present
studies was unique in that cells were grown in monolayer
culture attached to very small dextran beads maintained in
suspension through gentle stirring. ROS cells demonstrated
comparable PTH responsivenness in microcarrier culture as
was previously observed for cells grown on conventional
plasticware. PTH responses assayed were stimulation of cAMP
and inhibition of alkaline phosphatase. However, there are
mechanical agitation properties associated with microcarrier
culture which might affect PGE 2 release. ROS cells have been
shown to increase PGE2 release when subjected to mechanical
stretching (107), as has been observed in many other cell
types including flbroblasts (62). The possibility that
microcarrier culture induced alterations in AA metabolism
was examined by comparing [3H] release .from [3H]AA labelled
R0S cells maintained in microcarrier and stationary culture.
It was found that label release was identical for both
culture systems. In addition, transfer of cell samples from
microcarrier culture to stationary culture was not
associated with any redistribution of [3H]AA ithin
phospholipid classes. These results suggest that
microcarrier culture does not significantly affect
endogenous AA metabolism in R0S $7/2"8 cells.
The Ca++ ionophore, A-23187, was the only agent in or
study which st..mulated labelled
A-2387 facilitates Ca++ influx
AA release from R0S cells.
into cells which stimulates
phospholipase A 2 activity and AA release from phospholipids.
A 231 87 has been shown to be ineffective in other cell
systems in the absence of extracellular Ca ++ (55). In
addition, the Ca ++ binding protein, calmodulin, is also
implicated in A-23187 activation of phospholipase A 2, since
the calmodulin inhibitor, trifluoroperozine (TFP), will
block A-23187 effects on phospholipase A 2 in platelets
(104). PTH was expected to produce a response similar to A-
23187 since PTH has been shown to stimulate 45Ca uptake into
osteoblast enriched populations of freshly isolated bone
cells (18,19). Enhanced uptake of 45Ca uptake is generally
accepted as a measure of increased uptake of Ca++ by cells.
Since R0S 7/2"8 cells demonstrate comparable PTH responses
to osteoblast-enriched populations of bone cells, it was
anticipated that the R0S cell line would serve as a good
model to test this hypothesis. Because a significant dose of
PTH had.avirtually insignificant effect on AA release from
EOS cells relative to A-23187, it appears that PTH does not
elicit effects on R0S cells through a mechanism comparable
to A-231 87.
The inability of PTH to stimulate endogenous AA
metabolism in R0S 17/2"8 cells does not necessarily indicate
that hormonally stimulated osteoblasts _n _vi_v_o_ or in primary
culture respond in a similar manner. Recent evidence has
shown PTH stimulation of PGE production in osteoblast-
enriched cells (53). In addition, it is equally possible
that bone cells other than osteoblasts respond to PTH with
an increase in endogenous AA metabolism. It is not
established which cell types are responding under these
experimental conditions and the mechanisms regulating AA
metabolism. However, the inability to isolate pure
populations of individual bone cell types from intact bone
makes these findings difficult to resolve. Future research
in this area will be limited un.til relatively pure
populations of individual bone cell types can be
conveniently isolated.
The characterization of AA metabolism in HMP was an
extension of previous work by Rutherford and Schenkeln.
Together with other workers, these investigators
demonstrated enhanced 2 hour release of PGE and TXB2 from
C3b treated HMP. C3b treatment was also shown to decrease
HMP PI levels and increase sphingomyelin and
lysophosphatidylcholine levels over the same treatment
period. This preliminary work suggested that phospholipid-AA
metabolism might be important in regulating PGE and TXB 2
release from HMP. The present study therefore examined this
relationship by comparing the time course of 3HSAA release
from HMP phospholipids with the appearance of labelled PGE2
and TXB 2
In our view, the most exciting aspect of the monocyte
studies was th. differeutial pattern of eicosanoid release
following stimulation with C3b or LPS. Labelled AA release
occured within 2 hours of C3b or LPS stimulation without
significant conversion to labelled metabolites. Conversely,
the delay in labelled TXB 2 and PGE 2 release following C3b
treatment was not associated with increased AA release
during later time intervals. Lastly, the release of
immunoreactive and labelled TXB2 were very similar in C3b
treated cells whereas the time course of immunoreactive and
labelled PGE release were considerably different for the
same cell samples. These results suggest a more complicated
metabolic relationship between AA availability and
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prostanoid production than can be explained by enzyme
regulation alone.
The delay in TXB 2 and PGE2 release from stimulated HMP
appears to be unrelated to feedback regulation of AA
metabolite release. Although metabolite release was
determined in HMP-conditioned medium exchanged at specific
time points, this method of sequential medium harvesting did
not appear to significantly alter the cumulative release of
immunoreactive TXB 2 or PGE. Subsequent work in our
laboratory has shon that assessment of metabolite
production at intervals is comparable to cumulative
metabolite release over 2 hr. The sequential pattern o AA
mstabolite release from HMP is very interesting because it
may represent an additional aspect to monocyte regulation of
inflammation and tissue injury not addressed previously.
These results could have considerable importance to clinical
conditions which involve the release of prostanoids from
monocytes.
The sequential pattern of metabolite release is also
interesting with respect to mechanisms of C3b and LPS action
on HMP. Human monocytes have been shown to possess cell
membrane receptors for the complement cleavage products, C3b
and iC3b. Without rendering a detailed explanation of the
complement system (for which there are many excellent
reviews), C3b is a product of C3 convertase cleavage of C3
which can be activated by either the classical or alternate
complement pathways. The iC3b fragment is the product of C3b
cleavage by C3b inactivator but may also result from
proteolytic activity. Monocytes have been shown to
synthesize most complement proteins, including C3 as well as
C3b inactivator (98). The mechanism by -hich LPS stimulates
HMP eicosanoid production is unknown but could involve
cleavage on HMP membranes since LPS is a potent stimulator
of the alternate complement pathway. LPS generated C3
fragments could then act through cell membrane receptors in
stimulating eicosanoid release. The essential point to be
made is that C3b or LPS stimulate very similar patterns of
AA metabolits release from HMP. In addition, the increased
metabolite release occurs after a delay of at least 2 hours
after factor treatment. The release of labelled AA during
the initial 2 hour treatment period probably represents
plasma membrane phospholipid alterations more directly
associated with C3b or LPS membrane receptor interaction or
LPS treatment. On the other hand, the delay in peak release
of TXB 2 and PGE after C3b or LPS treatment suggests that
perhaps protein synthesis and/or RNA synthesis must take
place for stimulation of metabolite production. Because the
time between factor treatment and metabolite release is
considerable and unusual, this cell system may provide
insight into additional cellular mechanisms regulating AA
metabolism.
As described in Chapter II, the differentiation of
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immunoreactive from labelled PGE release suggests
independent metabolism of this eicosanold from TXB 2.
Ultimately, it
[3HSAA labelling
will be necessary to establish different
conditions which demonstrate labelled PGE2
release in parallel with immunoprecipitable PGE. It is
presumed that these conditions will be different from those
already established for parallel i.mmunoprecipitable and
labelled TXB 2 release. The first approach to this question
.’i.ll be to use longer labelling periods with [3H]AA prior
to stimulating with LPS or C3b. Longer labelling periods
should incorporate more 3HSAA into cellular lipid pools as
ll as allow for greater redistribution of AA into more
slowly equilibrating lipid pools. The previous results
suggest that most PGE can only be derived fom a lipid pool
which labels very slowly in the presence of exogenous K3HIAA
but which contains or is provided ith significant amounts
of unlabelled AA under stimulated conditions. By exposing
cells to K3HSAA for longer periods, it should be possible
incorporate sufficient label into these sequestered lipid
pools to measure K3HSPGE 2 release which parallels
immunoprecipitable PGE release.
Another approach to this problem is to determine the
time course of AA Ibss from lipid classes in HMP follozing
stimulation with C3b or LPS. This approach is less sensitive
than the previously described labeling studies because of
the complex lipid manipulations and because of the
relatively low levels of AA held within certain lipid
classes in HMP. Hewever, this approach should alse provide
insight into the lipids hich are contributing to PGE
release as well as TXB2 and AA release.
The preliminary determinations of C3b-stimulated 3HAA
release frem HMP phospholipids indicate that AA is released
principally from PI and PC. Further examination of C3b
effects on HMP phospholipid labeling has been delayed so
that a more extensive characterization of HMP phospholipids
can be carried out. Recent data have demonstrated that
rabbit and guinea pig macrophages possess significant levels
of alkenyl-acyl and alkyl-acyl choline phosphoglyceride
(CPG) and ethanolamine phosphatidylglyceride (EPG) (89,90).
Alkenyl-acyl and alkyl-acyl phospholipids are distinguished
from diacyl lipids in that the chemical moiety linked to the
position of glycerol forms an ether or an alkyl bond. Also
noteworthy is that alkenyl and alkyl phospholipids of rabbit
and guinea pig macrophages contain significant levels of AA
(90) and that alkyl-acyl CPG may serve as a precursor
molecule in the synthesis of platelet activating factor
(PAF). PAF has been shown to stimulate PGE and TXB2 release
from peritoneal macrophages.
Alkyl-acyl and ether-acyl phos.pholipids cannot be
discriminated from diacyl phospholipids by conventional
and 2 dimensional thin layer chromatography. However,
methods are now available to conveniently characterize all
100
three c!as ses of these phospholipids (94). Because AA
release from PC is stimulated by C3b treatment of HMP, it is
important to determine whether this release is selective for
a particular class of choline phosphoglyceride. Experiments
are therefore planned to first determine whether HMP contain
significant levels of alkenyl-acyl or ether-acyl
phospholipids and subsequently examine whether C3b or LPS
can stimulate AA release.
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